Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Mubritinib (TAK 165): Target-to-Assay Guide
2026-08-20
Mubritinib (TAK 165) is more than a historical HER2 inhibitor: it is a mechanistic probe of mitochondrial complex I, OXPHOS dependence, and protein binding. This guide translates its HSA interaction data into more interpretable AML, PEL, and cancer biology assays.
-
UK-5099 for Whole-Blood Immunometabolism
2026-08-20
UK-5099, also known as PF-1005023, lets researchers test how mitochondrial pyruvate entry shapes cytokine responses without broadly removing extracellular glucose. This practical guide connects standardized whole-blood stimulation with mitochondrial respiration, insulinoma-cell assays, and glucose homeostasis studies while emphasizing controls, dose design, and troubleshooting.
-
Canagliflozin and Mitochondria in Diabetic Kidney Cells
2026-08-19
Trentin-Sonoda and colleagues show that Canagliflozin improves mitochondrial network architecture and bioenergetic performance in proximal tubular cells from hypertensive–diabetic mice. The sex-dependent findings extend SGLT2 inhibitor research beyond glucose lowering and provide a mechanistic framework for studying renal protection in diabetic kidney disease.
-
Elobixibat Hydrate: From IBAT to Translational Insight
2026-08-19
Elobixibat hydrate offers a compelling model of compartment-focused pharmacology: local ileal bile acid transporter inhibition can reshape colonic signaling, motility, and metabolic readouts without requiring high systemic exposure. This thought-leadership article connects IBAT biology with peristaltic-reflex research and provides a practical framework for translational validation.
-
Sulfo-Cy3 azide for Neurodevelopmental Mapping
2026-08-18
Sulfo-Cy3 azide combines aqueous compatibility with bright orange-red fluorescence for labeling alkyne-bearing biomolecules, including oligonucleotides and potential EdU-based birthdating assays. This guide translates a rat claustrum development study into practical Click Chemistry fluorescent labeling, imaging, and troubleshooting workflows.
-
Berberine Hydrochloride: A Causal Assay Map
2026-08-18
Berberine hydrochloride connects AMPK-centered metabolism with microbiome, tuft-cell, and osteoimmune biology. This article presents a causal assay framework for separating direct cellular effects from gut-mediated mechanisms in metabolic and bone research.
-
UK-5099: A Mechanistic Lens on Immunometabolism
2026-08-17
UK-5099 (PF-1005023) is a mitochondrial pyruvate carrier inhibitor for connecting substrate transport with cellular phenotype. This article presents a decision framework for applying it across mitochondrial metabolism research, immune assays, and glucose-homeostasis studies without confusing transport blockade with global glycolytic inhibition.
-
Fludarabine Workflows for Oncology Research
2026-08-17
Fludarabine provides a practical way to connect DNA replication stress with cell-cycle and apoptosis readouts in leukemia and multiple myeloma models. This guide covers formulation, dose-response design, mechanistic validation, genotype-aware assay planning, and troubleshooting for reproducible bench studies.
-
HBTU for Precision Peptide Synthesis
2026-08-16
HBTU streamlines carboxylic acid activation for rapid, high-yield peptide bond formation in solid phase and solution workflows. Its practical value is especially clear when building enzyme-responsive peptide amphiphiles, where sequence fidelity, low racemization risk, and reproducible coupling directly influence downstream self-assembly assays.
-
ML216 BLM Helicase Inhibitor Workflow Guide
2026-08-15
ML216 enables mechanism-focused interrogation of BLM-dependent DNA repair, from helicase assays and sister chromatid exchange to cell proliferation and chemotherapy-sensitization studies. This workflow emphasizes target controls, solvent discipline, and careful interpretation when extending BLM findings to WRN- or MSI-driven cancer models.
-
Mc-Val-Cit-PABC-PNP ADC Linker Workflow
2026-08-14
Mc-Val-Cit-PABC-PNP is a cathepsin-cleavable ADC peptide linker for research workflows investigating payload release after lysosomal processing. This guide covers solvent handling, conjugation setup, QC, and limitations; the material is not intended for aqueous formulation, diagnostic use, or medical and therapeutic applications.
-
RIPA Lysis Buffer (Strong) for Bone Protein Workflows
2026-08-14
Build reproducible bone-cell and tissue lysates for Western blotting, immunoprecipitation, and signaling studies with a stringent detergent system. This workflow connects prenatal dexamethasone research to practical sample handling, inhibitor control, and assay-specific optimization.
-
Drug-Sensitized Yeast for mTOR Inhibitor Discovery
2026-08-13
Breen and colleagues developed a genetically drug-sensitized Saccharomyces cerevisiae platform that detects TOR inhibitors at substantially lower concentrations than a wild-type yeast background. The system distinguishes TOR1-dependent growth inhibition and provides a practical first-pass screen, while also showing that several tested compounds, including canagliflozin, produced no detectable TOR-inhibitory phenotype under the study conditions.
-
IR-820 (New Indocyanine Green) Imaging Guide
2026-08-13
IR-820, also called New Indocyanine Green, is a near-infrared dye for research imaging of blood-pool and diseased-tissue contrast. Its fluorescence supports vascular imaging and tumor-model workflows, but quantitative performance depends on experimental calibration and should not be inferred from an indocyanine-green nanotherapy study.
-
Drug-Sensitized Yeast for mTOR Inhibitor Discovery
2026-08-12
The 2025 GeroScience study develops a drug-sensitized Saccharomyces cerevisiae platform that markedly improves detection of TOR/mTOR pathway inhibitors. Its growth-based design identifies known catalytic inhibitors and aminophylline while showing that canagliflozin does not produce TOR1-dependent inhibition in this model, clarifying both the platform’s utility and its biological boundaries.